Head and Neck Cancer Research

Current Projects

• Insulin-like growth factor-1 receptor (IGF1R)-induced resistance to targeted therapy in head and neck squamous cell carcinoma (HNSCC): identifying predictors and determining the utility of IGF1R antagonism
• IGF1R expression in HNSCC as a predictor of sensitivity to adjuvant EGFR inhibition
• Treatment of HNSCC with novel combinations of targeted therapeutics: methods of predicting successful tumor growth inhibition
• Molecular predictors of response to chemoradiotherapy in head and neck squamous cell carcinoma with special focus on impact of HPV infection
• Novel cancer-gonad antigens in head and neck squamous cell carcinoma: determining value as diagnostic biomarkers and/or therapeutic targets
• Nanoliposome-delivered ceramide as a novel therapy for HNSCC
• Interrogation of tumor response to therapy using microsampling and nanoimmunoassay
• Predictors of outcome after major head and neck reconstructive surgery: improving cost-effectiveness and function
• Oncologic, functional and quality of life outcomes after transoral robotic surgery (TORS)
• Utility of adipose-derived stem cells in head and neck reconstruction; impact on behavior of head and neck cancers

Clinical Trials

UVA Head and Neck Innovative Treatment Group / Theraclion
A pilot study to evaluate the feasibility and safety of high intensity focused ultrasound for treatment of papillary thyroid cancer (pending)

Ludwig Institute for Cancer Research LUD2014-011
A phase 1/2 study of in situ vaccination with tremelimumab and IV durvalumab (MEDI4736) plus the Toll-like receptor agonist polyICLC in subjects with advanced, measurable, biopsy-accessible cancers (pending)

Bristol-Myers Squibb BMS CA209-651
An open label, randomized, two arm phase III study of nivolumab in combination with ipilimumab versus extreme study regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first line therapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (pending)

Phase II randomized trial of adjuvant radiotherapy with or without cisplatin for p53 mutated, surgically resected squamous cell carcinoma of the head and neck (SCCHN) (pending)

Merck MK-3475-048, IRB# 18172
A phase 3 clinical trial of pembrolizumab (MK-3475) in first line treatment of recurrent/metastatic head and neck squamous cell carcinoma
10/2015 – present

ECOG-ACRIN #3311, IRB# 17965
Phase II randomized trial of transoral surgical resection followed by low-dose or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer
10/2015 – present

UVA Otolaryngology – Head and Neck Surgery, IRB# 16376
A single arm study of efficacy and functional quality of life in patients treated with transoral robotic surgery for oropharyngeal and supraglottic squamous cell carcinoma
8/2012 – present

UVA Otolaryngology – Head and Neck Surgery, IRB# 14245
Assessment of predictive biomarkers in head and neck squamous cell carcinoma

National Institute of Dental and Craniofacial Research (NIDCR) / M D Anderson Cancer Center
Tissue bank consortium for salivary gland tumors
8/2008 – present